CAVA vs. Krispy Kreme: Which Consumer Stock Is a Better Buy in 2026?

CAVA reported FY2025 revenue of nearly $1.2 billion, up 22.4%, with net income of about $63.7 million and free cash flow of $26.1 million, while Krispy Kreme posted an 8.6% revenue decline to about $1.5 billion, a net loss of $515.8 million, and negative free cash flow of $64.0 million. The article favors CAVA on growth and profitability despite its premium valuation, while framing Krispy Kreme as a higher-risk turnaround with a lower sales multiple and a 2026 free cash flow target of $15 million. Overall tone is constructive on CAVA but mixed across both names due to valuation and execution risks.

Analysis

The market is effectively pricing CAVA as a long-duration compounding asset and DNUT as an optionality-on-turnaround story. That asymmetry matters: CAVA’s premium multiple only works if same-store growth and unit growth stay near current cadence for several more years, while DNUT’s discount can stay cheap because the turnaround is balance-sheet constrained and execution-heavy. In other words, CAVA is “expensive but financeable”; DNUT is “cheap but fragile.”

Second-order, CAVA’s expansion is likely to pressure adjacent fast-casual peers more than it cannibalizes itself. The strongest read-through is to CMG and, to a lesser extent, SBUX/MCD in the lunch/dinner occasion: if CAVA keeps taking share in the healthier convenience segment, the competitive response will be menu inflation, discounting, or faster rollout cadence, which can compress returns on new units across the group. DNUT’s pivot to third-party points of access may improve top-line visibility, but it also commoditizes the brand and shifts bargaining power to retailers, meaning the gross profit mix could improve less than headline distribution growth suggests.

The key risk on CAVA is not demand—it is duration of execution. At roughly 140x forward earnings, any slowdown in unit productivity or a couple quarters of margin slippage can de-rate the stock sharply, but the downside is cushioned by positive earnings, liquidity, and a cleaner balance sheet. DNUT’s risk is the opposite: if the expected cash flow inflection slips even modestly, leverage and weak working capital make the equity vulnerable to another leg lower before the market ever rewards the restructuring.

Consensus is probably underestimating how much better CAVA’s quality of growth is versus DNUT’s “headline growth.” The contrarian view, however, is that CAVA may already be fully owned by growth investors, while DNUT has enough embedded skepticism that any credible evidence of sustained free cash flow could trigger a violent rerating. For 2026, this looks less like a value-vs-growth debate and more like a balance-sheet versus duration trade.

Key Decisions for Investors

• Long CAVA / short DNUT as a 6-12 month quality-vs-restructuring pair trade; thesis is that CAVA can sustain premium compounding while DNUT remains balance-sheet capped. Risk: CAVA multiple compression if growth normalizes faster than expected.
• Buy CAVA on 10-15% pullbacks only, not into strength; use a 3-6 month window and insist on a better entry because the stock is paying you almost nothing for execution risk at current valuation.
• Avoid outright long DNUT until there is at least 2 consecutive quarters of positive free cash flow ex-stock-based compensation; current setup is a classic value trap unless operating leverage shows up fast.
• For higher-risk accounts, consider a small DNUT call spread 9-12 months out as a turnaround option, financed against a short position in a broader discretionary basket. Reward is asymmetric, but position size should be minimal because leverage and weak liquidity can overwhelm the equity before the thesis plays out.
• Watch CMG and MCD for competitive-response signals over the next 1-2 quarters; if CAVA continues taking lunch/dinner share, expect promotions and unit-growth acceleration elsewhere, which can create short opportunities in the most crowded premium fast-casual names.